v3.25.4
Revenue from collaboration agreements (Tables)
12 Months Ended
Dec. 31, 2025
Revenue [abstract]  
Summary of Deferred revenue related to the collaboration agreements

Deferred revenue related to the collaboration agreements consists of the following:

 

 

As of

 

 

December 31,
2025

 

 

December 31,
2024

 

 

(Euros in thousands)

 

Current

 

 

15,816

 

 

 

35,908

 

Non-current

 

 

18,541

 

 

 

34,161

 

Total

 

 

34,357

 

 

 

70,069

 

Summary of revenue from collaboration agreements explanatory

Revenue from collaboration agreements was realized with the following partners:

 

 

Year ended December 31,

 

 

2025

 

 

2024

 

 

2023

 

 

(Euros in thousands)

 

Revenue from collaboration agreements:

 

 

 

 

 

 

 

 

 

Moderna, United States

 

 

37,247

 

 

 

62,785

 

 

 

5,369

 

BMS, United States

 

 

11,019

 

 

 

78,099

 

 

 

50,695

 

Genmab, Denmark

 

 

 

 

 

14,951

 

 

 

(2,067

)

Total

 

 

48,266

 

 

 

155,835

 

 

 

53,997